Press Releases
AtriCure to Announce Second Quarter 2025 Financial Results
July 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Jul. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter...
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 23, 2025
MASON, Ohio --(BUSINESS WIRE)--May 23, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports First Quarter 2025 Financial Results
April 29, 2025
Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year MASON, Ohio --(BUSINESS WIRE)--Apr....
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
April 10, 2025
MASON, Ohio --(BUSINESS WIRE)--Apr. 10, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ®...
AtriCure to Announce First Quarter 2025 Financial Results
April 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter...
AtriCure to Host Analyst & Investor Day on March 26, 2025
March 12, 2025
MASON, Ohio --(BUSINESS WIRE)--Mar. 12, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst...
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
February 12, 2025
Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE ® +, cryoSPHERE MAX ™ and AtriClip ® FLEX-Mini ™ devices in the United States , and EnCompass ®...
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
January 22, 2025
MASON, Ohio --(BUSINESS WIRE)--Jan. 22, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth...
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
January 13, 2025
MASON, Ohio --(BUSINESS WIRE)--Jan. 13, 2025-- AtriCure, Inc. (Nasdaq: ATRC) , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for...
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
MASON, Ohio --(BUSINESS WIRE)--Dec. 23, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...